Introduction
Subthalamic nucleus (STN) deep brain stimulation (DBS) is well established as a treatment option for advanced Parkinson's disease (PD) improving motor symptoms [1] , quality of life (QoL) [2] and non-motor symptoms (NMS) [3] on a group level.
However, studies investigating outcomes on the subject level indicate that a considerable proportion of patients (between 43-49%) do not experience a relevant QoL improvement after STN-DBS [4, 5] . Data on the preoperative determinants QoL outcome are scarce and suggest a role of some motor aspects, such as long daily off time [4] or small levodopa challenge test response [6] , as well as some neuropsychiatric factors, such as high apathy scores [7] . In the present study, we therefore conducted a comprehensive assessment of a wide range of non-motor and motor symptoms to explore predictors of beneficial QoL outcome after STN-DBS. We hypothesized that NMS can predict QoL outcome after DBS.
Methods

Study design
In this ongoing, prospective, open-label, multicenter, international study (Cologne, London, Manchester) we examined patients with PD undergoing bilateral implantation of stimulation electrodes for STN-DBS in the DBS arm [3] of the EuroInf study at preoperative baseline and follow-up 6 months after surgery. Data from 35
patients was included in a previous analysis published by our group on beneficial non-motor effects of STN-DBS in a large cohort of patients with PD [3] .
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Ethical approval
The study was carried out in accordance with the Declaration of Helsinki and approved by local ethics committees (Cologne, study no.: and an exclusion of clinically relevant cognitive impairments and psychiatric diseases in assessments by expert neuropsychologists and psychiatrists.
Clinical assessment
The following scales and questionnaires were assessed, as previously reported in the EuroInf study [3, 9, 10] . All scales were assessed preoperatively in a clinical MedONand postoperatively in a clinical MedON/StimON-state.
Quality of life
QoL was assessed with the PD Questionnaire-8 (PDQ-8) [11] which has previously been used for patients with PD and STN-DBS [12, 13] . The PDQ-8 surveys the frequency of the following eight aspects of QoL: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, bodily changes, and sweating). NMSS total score ranges from 0 (no NMS) to 360 (maximum NMS) [16] .
-The Hospital Anxiety and Depression Scale (HADS) which consists of subscales testing anxiety and depression with seven items respectively. Subscales range from 0 (no anxiety/depression) to 21 (maximum anxiety/depression) [17] .
Motor manifestation
Motor examination, activities of daily living, and motor complications were assessed with Scales for Outcomes in Parkinson's disease (SCOPA-A, -B, -C) which strongly correlate to the UPDRS and were derived from this scale [18] . The SCOPA was used for time economic reasons as its assessment time is approximately 4 times shorter than for the MDS-UPDRS [18] [19] [20] . We explored the relationship between preoperative demographic and clinical features and QoL outcome in the following analyses. c. Dichotomization into "responders"/"non-responders" and logistic regression analyses
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We divided the cohort into groups with and without clinically relevant QoL improvement ("responders"/"non-responders") based on a designated threshold (≥½ SD of PDQ-8 SI baseline ) [3] which is a method that has been shown to reliably report clinically important differences [22] . We then calculated the proportion of "responders" based on this threshold.
Exploratory logistic regression models with dichotomized QoL outcome as dependent and demographic factors and preoperative clinical parameters as independent variables were employed to confirm the utility of linear regression models to predict patients' postoperative QoL changes. Additionally, Mann-Whitney U tests were computed to confirm Test baseline differences between "responders"/"non-responders".
d. Exploratory analyses of NMSS item scores
As we were interested in the relationship of QoL changes and specific aspects of NMS, all analyses were also carried out for NMSS item scores.
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Results
Our study included 88 patients with PD (56 male) with mean age at intervention=61.2 years (SD=8.1) and disease duration=10.5 years (SD=4.5). Here we present data from 30 patients from Manchester, 22 patients from London, and 36 patients from
Cologne. The mean time to follow-up from surgery was 5.49 months (SD=0.86).
Changes of outcome parameters from baseline to follow-up
All outcome parameters significantly improved on follow-up (see table 1 ). As PDQ-8 SI significantly improved, we explored changes of its domain scores: All domains, except 'Cognition', improved significantly (see figure 1 and supplemental table A).
Relationship between baseline quality of life and changes of other
outcomes a. Spearman-correlation analyses 
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Discussion
In this prospective, open-label, multicenter, international study including a cohort of 88 patients with PD, STN-DBS significantly improved QoL, motor and non-motor outcomes as well as medication requirements on 6 months follow-up after surgery.
However, we observed considerable inter-individual variance as only 56.3% of patients experienced a clinically relevant improvement of QoL ("QoL responders").
The remaining 43.7% of patients were to be classified as "QoL non-responders", a rate well within the range of other cohorts (41-49%) [4, 5] . To address the unmet need of identifying factors which contribute to this high inter-individual variance, we evaluated the non-motor, motor, and demographic predictors of QoL outcome:
Non-motor predictors of quality of life
As a key finding of our study, we observed that preoperative non-motor aspects of PD, i.e. "difficulties in experiencing pleasure" and "high frequency of voiding", were We explored not only preoperative QoL and motor symptoms but also NMS as potential predictors of QoL outcome because of the emerging concept of non-motor effects of DBS [24, 25] . This concept is based on evidence from comprehensive assessments with clinician-based and self-reported patient-based scales, e.g. for depressive symptoms [26] , pain [27] , sleep [28] , gastrointestinal symptoms, excessive sweating, and perceptual problems/hallucinations [3] , and also backed by a growing number of studies using laboratory-assisted objective measures for specific NMS, e.g. polysomnography for sleep [29] , 13 CO 2 excretion for gastric emptying [30] , urodynamic examination for urinary symptoms [31] , caloric chambers for daily energy expenditure/weight changes [32] , and sympathetic skin response for excessive sweating [33] . Furthermore, our previous work has provided evidence that patients with stronger postoperative improvement of NMS experience significantly more QoL improvement [3] .
To understand the predictive potential of specific NMS for QoL outcomes in DBS several factors may be important:
1. The strong link between QoL and NMS in PD is well known [34, 35] . As specific NMS are amenable to DBS their alleviation potentially also improves QoL. In this context the following mechanisms may play a role: Mood [36, 37] could be affected by a modulation of associative basal ganglia-thalamocortical loops and autonomic symptoms like bladder control [31] and pain [27] by limbic circuitry. Furthermore, local effects may play a role, i.e. via the spread of current to brain brain regions next to the STN: The lateral hypothalamus could, e.g., be modulated which may result in weight changes [38] . 2. An improvement of sensory gaiting/processing: Previous studies have provided evidence that this PD-related pathopysiological mechanism is amenable to DBS but not necessarily to dopaminergic medication, e.g., in specific types of pain [39] , bladder control [31] and auditory deficits [40] .
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Therefore, high preoperative severities of these NMS may be a surrogate marker for beneficial NMS outcome which may result in beneficial QoL outcome.
3. Neuropsychiatric symptoms, such as depression and anxiety, are particularly important for DBS outcomes. A failure to improve in these symptoms can diminish subjective QoL outcome [7] . Consistent with findings from previous studies [5, 7] , step-wise linear regressions showed that more improvement of "flat moods" and "difficulties experiencing pleasure" is an important determinant of more QoL improvement. One has to acknowledge that, unlike these NMSS items, HADS total scores did not predict QoL outcomes in our cohort. This discrepancy may result from the fact that these items flat moods and difficulties experiencing pleasure are more specific, whereas HADS total scores summarize a wider range of anxiety and depression symptoms.
4. The reduction of non-motor and motor fluctuations due to the continuous effects of DBS may play an important role. Previous studies have provided evidence for an improvement of non-motor fluctuations of depressive mood and bladder urgency by DBS [41] . Furthermore, weight changes may stabilize in a subset of patients as a reduction of, e.g., dykinesia, rigidity and tremor resulting from motor fluctuations may alleviate excessive energy expenditure [42] . We found a predictive potential for QoL improvement in all these symptoms. In line with previous results [5, 43] , we found that higher preoperative QoL impairment is a significant predictor of more postoperative QoL improvement. As regards the relationship between preoperative PDQ scores and postoperative PDQ outcomes our result of an OR=1.05 remarkably resembles results of the Cleveland Clinic cohort (same OR=1.05). In line with previous studies, we observed no improvement of the cognition domain [2, 5] . The confirmation of these results in an independent cohort emphasizes the validity of our results and the high test-retest validity of the PDQ [5] .
Preoperative motor manifestation
In line with previously published studies in other cohorts [4, 5] , we observed no significant predictive value of motor examination scores in our cohort. While there were negative results in previous studies regarding a relationship between preoperative UPDRS-III and postoperative QoL outcome, there was, however, evidence for a relationship with the response to dopaminergic medication, either directly (preoperative improvement in the levodopa challenge test) or indirectly (preoperative daily cumulative off time). We did not investigate levodopa response as all patients included in our study were required to fulfill the criterion of >30% UPDRS-III improvement in the levodopa test to be eligible for DBS surgery.
Consequently, there is lack of patients with little improvement in the levodopa test and our cohort size was not powered for an analysis of the relationship between levodopa response and QoL outcome after STN-DBS. In fact, a retrospective study M A N U S C R I P T influence QoL [44] . As regards gender differences, our results are in line with previous studies which have provided evidence for a significantly better QoL outcome in female patients undergoing DBS which may result from more subjective improvement of functional autonomy in women than in men [45] .
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Limitations
There are a number of limitations of this study.
As a prospective DBS registry study this was not a randomized or double-blinded study with a best medical treatment control group. However, as a prospective study reliability of data is likely to be better than in retrospective studies and its multicenter design is likely to reduce the potential bias of a single-center design. One has to acknowledge selection bias due to several factors: As per clinical routine patients with dementia or severe depression were not eligible for DBS. Additionally, only Regarding the statistical analysis, the choice of a cut-off value for the classification into "responders"/"non-responders" is a crucial point. Previous studies have employed the same method to derive a cohort-specific cut-off value (≥½ SD of PDQ-8 SI baseline ) [3, 22] . The calculated cut-off=8.22 in our cohort was similar to a general PD population in which the reliable change index resulted in a cut-off=7.0 on the PDQ-39 SI (10.9 on the PDQ-39 total score) [4] . As the reliable change index is considered to be a conservative method for the calculation of clinically important difference in QoL [4] and our calculated threshold was comparable, we too applied a conservative cut-off for all logistic regression analyses.
As explained in the supplemental material A section 1, there is a considerable overlap between the contents of questions of the PDQ and NMSS which may cause false postive results for the predictor analysis. To minimize this confounding effect, we additionally carried out all analyses with a modified PDQ score in which corresponding PDQ items were left out when respective NMSS items were tested and reincluded for analyses with all other NMSS items. The analyses with this modified PDQ by large confirmed the original results with the unmodified PDQ-8
which increases the reliability of the results (see supplemental material A section 2.1 and 2.2). As regards the motor scales used in the present study, SCOPA scores may offer limited comparability with (MDS)-UPDRS scores assessed in other studies.
However, like the MDS-UPDRS the SCOPA is a reliable and valid instrument, the assessment of the SCOPA is approximately four times shorter making the scale more time-efficient, and conversion formulae between these scales are available [18] [19] [20] .
Although the current work includes one of the biggest cohort sizes in studies of its kind (n=88), increased cohort sizes are required to employ more sophisticated M A N U S C R I P T
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Running title: "QoL after STN-DBS depends on NMS in PD" page 20 / 24 analyses, such as clustering and a stratification of outcomes. Additionally, assessments of further symptoms, such as impulsivity and apathy, could add value to predictive models [7] . Furthermore, from our relatively short follow-up, we cannot predict which factors contribute to long-term QoL improvement, in particular, as in some patients a relatively long time may be required to find stable effective stimulation parameters or to recover from medication withdrawal. A longer follow-up including neuropsychological and non-dopaminergic NMS as well as axial motor symptoms, such as falls, is required to address the long-term QoL outcome [46, 47] .
The non-motor scales employed in this study survey NMS over a time period of four weeks prior to assessment summarizing ON and OFF times and therefore are not feasible to study the microstructure of non-motor fluctuations. An investigation of nonmotor OFF times and fluctuations may help to understand the impact of NMS on QoL and to address this issue further studies are needed including non-motor patient diaries.
Conclusion
The novel findings of this study regarding the predictive value of global and specific NMS for QoL outcome emphasize the importance of a holistic assessment of patients prior to surgery. Future studies investigating preoperative motor and non-motor PD profiles, e.g., with clustering methods, may enable a more precise assessment of 
